ReviewMolecular biotechnology2019
Stopping Untreatable Pathogen Infections Using Peptide Ligands to Sabotage Pathogenic Cell Surface Proteins.
Review in Molecular biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- A proposed treatment for pathogenic enveloped viruses having high rates of mutation or replication.Scandinavian journal of immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specifically targeted peptide ligands can sabotage pathogenic cell surface proteins and stop increasingly untreatable pathogen infections. Different approaches might be used to sabotage pathogenic cell surface proteins to stop infections. A conjugation treatment uses carefully selected genetically modified plasmids prepared in advance to activate a secondary immune system response neutralizing pathogens with a new, much larger cascade of antibodies. Non-conjugation treatment introduces genetically modified cells into the center of localized pathogen infections to produce peptide ligands; and another non-conjugation treatment introduces only the peptide ligands into the center of localized pathogen infections to sabotage pathogenic cell surface proteins used to specifically infect mammalian cells. Extensive and meticulous plasmid transfer experiments by two separate groups firmly support the feasibility of extremely rapid and thorough plasmid transfer necessary for the conjugation treatment. A third independent group introduced genetically modified bacteria into mammals, including several human volunteers, with safe and effective experimental results, which also firmly supports the feasibility of the first non-conjugation treatment. These three approaches offer several profound advantages compared to treatments using new antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.